Saglio G et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month (mo) follow-up. Proc ASH 2011;Abstract 452.

Hughes TP et al. Complete molecular response (CMR) rate with nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) without CMR after ≥ 2 years on imatinib: Preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice daily (bid) vs imatinib. Proc ASH 2011;Abstract 606.

Hochhaus A et al. Results from the ENESTnd extension study: Efficacy and safety of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP), treated with nilotinib 400 mg twice daily (bid) after suboptimal response (SoR) or treatment failure (TF) to imatinib 400 mg once daily (qd) or nilotinib 300 mg bid. Proc ASH 2011;Abstract 114.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.